Commentary|Videos|November 16, 2026

Madhav Seshadri, MD, Maps Unmet Needs in Aggressive Lymphomas

Fact checked by: Laura Joszt, MA

The UCSF Health–based leukemia and lymphoma specialist outlines chemo-free DLBCL, dual-targeted CAR T-cell therapy, and MRD-guided deescalation.

Madhav Seshadri, MD, an assistant professor in the malignant hematology group at UCSF Health, who specializes in lymphoma and chronic lymphocytic leukemia, sees clear gaps in the treatment of aggressive lymphomas. He also sees promising ways to close those gaps.

In this interview with The American Journal of Managed Care®, he spoke first of artificial intelligence (AI). Many clinicians now use tools such as OpenEvidence to support clinical decision-making, and he said that although AI can be a helpful reference, it cannot be an outright substitute for judgment. Clinicians should treat it as offering suggestions, but that “everything needs to be verified.” Decisions, he said, should rest on a solid understanding of both the evidence and the individual patient.

On unmet needs, he focused on aggressive lymphomas, starting with first-line treatment of diffuse large B-cell lymphoma in older patients and those with significant comorbidities, who may not tolerate CHOP-based (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) chemotherapy-free regimens that pair immunotherapies and bispecific antibodies with immunomodulatory and targeted agents. Early data are promising but are not yet mature.

The second great need is for relapse care after chimeric antigen receptor (CAR) T-cell therapy or bispecific antibody administration. Seshadri sees these relapses frequently, with limited treatment options. One approach is CAR T-cell therapy that targets CD19 and CD20, aiming to overcome loss of target antigen, a common escape mechanism. Several trials are testing dual targeting of cells and other antigens. The third great need is deescalating therapy based on measurable residual disease (MRD) status, an approach that extends to mantle cell lymphoma and Hodgkin lymphoma.

Seshadri sees MRD testing as central to where the field is heading. “I think that as MRD testing becomes better, using that as a very sensitive way to risk stratifying patients and trying to better select treatments with a better benefit and risk ratio for those patients is an exciting area of research,” he said.


Related to this article